Split course or protracted radiotherapy combined with cisplatin (CDDP) and fluorouracile (5-FU) for patients with resectable locally advanced esophageal cancer: Results based on a randomized phase III trial from the fondation francaise de cancerologie digestive: FFCD no. 9102.

被引：0
|
作者：
Crehange, G.
Bonnetain, F.
Seng, S.
Nguyen, T.
Mirabel, X.
Marchal, C.
Verrelle, P.
Roullet, B.
Bedenne, L.
Maingon, P.
机构：
[1] Ctr GF Leclerc, F-76038 Dijon, France
[2] Ctr Henri Becquerel, Rouen, France
[3] Inst J Godinot, F-59020 Reims, France
[4] Ctr Oscar Lambret, Lille, France
[5] Ctr A Vautrin, Nancy, France
[6] Ctr Jean Perrin, Clermont Ferrand, France
[7] Univ Hosp Dupuytren, Limoges, France
[8] Univ Hosp Le Bocage, Dijon, France
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2006年 / 66卷 / 03期
关键词：
D O I：
10.1016/j.ijrobp.2006.07.172
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
141
引用
收藏
页码：S79 / S79
页数：1
相关论文
共 8 条
  • [1] Impact of the radiation regimen on local control and survival for patients with resectable locally advanced oesophageal cancer treated with chemoradiation: Results based on randomized phase III trial from the "Federation Francaise De Cancerologie Digestive"
    Maingon, P.
    Bonnetain, F.
    Seng, S-H.
    N'Guyen, T. D.
    Mirabell, X.
    Marchal, C.
    Verrelle, P.
    Roullet, B.
    Resbeut, M.
    Janoray, P.
    Bedenne, L.
    Crehange, G.
    RADIOTHERAPY AND ONCOLOGY, 2006, 81 : S193 - S194
  • [2] Impact of radiation (RT) regimen on palliative procedures (PP) for patients with resectable locally advanced esophageal cancer treated with exclusive chemoradiation (CRT) or preoperative chemoradiation (CRT plus S): results from a phase III trial of the Federation Francophone de Cancerologie Digestive (FFCD 9102)
    Crehange, G.
    Bonnetain, F.
    Seng, S.
    N'guyen, T.
    Mirabel, X.
    Marchal, C.
    Verrelle, P.
    Roullet, B.
    Maingnon, P.
    Bedenne, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [3] Interim safety results from a phase II/III trial with 5-FU, oxaliplatin, and docetaxel (FLOT) versus epirubicin, cisplatin, and 5-FU (ECF) in patients with locally advanced, resectable gastric/oesophagogastric junction (OGJ) cancer: A study of the AIO.
    Koock, Ulrike
    Pauligk, Claudia
    Luley, Kim Barbara
    Mayer, Frank
    Schulmann, Karsten
    Homann, Nils
    Schmalenberg, Harald
    Hozaeel, Wael
    Hofheinz, Ralf
    Probst, Stephan
    Mahlberg, Rolf
    Koenigsmann, Michael
    Haag, Georg Martin
    Meiler, Johannes
    Prasnikar, Nicole
    Behringer, Dirk M.
    Trojan, Jorg
    Egger, Matthias
    Jaeger, Elke
    Al-Batran, Salah-Eddin
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [4] A phase III trial comparing 5-FU plus cisplatin (CF) versus CF plus docetaxel or radiotherapy as neoadjuvant treatment for locally advanced esophageal cancer: 5-year follow-up from JCOG1109
    Kato, Ken
    Ito, Yoshinori
    Daiko, Hiroyuki
    Ozawa, Soji
    Ogata, Takashi
    Hara, Hiroki
    Kojima, Takashi
    Abe, Tetsuya
    Bamba, Takeo
    Watanabe, Masaya
    Kawakubo, Hirofumi
    Shibuya, Yuichi
    Tsubosa, Yasuhiro
    Takegawa, Naoki
    Kajiwara, Takeshi
    Baba, Hideo
    Ueno, Masaki
    Machida, Ryunosuke
    Nakamura, Kenichi
    Kitagawa, Yuko
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [5] Cisplatin/5-FU (CF) +/ panitumumab (P) for patients (pts) with non-resectable, advanced, or metastatic esophageal squamous cell cancer (ESCC): An open-label, randomized AIO/TTD /BDGO/EORTC phase III trial (POWER).
    Moehler, Markus H.
    Thuss-Patience, Peter C.
    Brenner, Baruch
    Longo, Federico
    Meiler, Johannes
    Ettrich, Thomas Jens
    Hofheinz, Ralf
    Al-Batran, Salah-Eddin
    Vogel, Arndt
    Mueller, Lothar
    Lutz, Manfred P.
    Borchert, Kersten
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [6] Capecitabine (Cape) versus 5-fluorouracil (5-FU)-based (neo-)adjuvant chemo-radiotherapy (CRT) for locally advanced rectal cancer (LARC): Long-term results of a randomized, phase III trial
    Hofheinz, R-D
    Wenz, F.
    Post, S.
    Matzdorff, A.
    Laechelt, S.
    Hartmann, J. T.
    Mueller, L.
    Link, H.
    Moehler, M.
    Kettner, E.
    Fritz, E.
    Hieber, U.
    Lindemann, H. W.
    Grunewald, M.
    Kremers, S.
    Constantin, C.
    Hipp, M.
    Gencer, D.
    Burkholder, I
    Hochhaus, A.
    ONKOLOGIE, 2011, 34 : 199 - 199
  • [7] Definitive results of the French FFCD-SFRO 2000-01 study: Phase III trial comparing chemoradiotherapy (Cisplatin and infusional 5-FU) followed by gemcitabine vs. gemcitabine alone in patients with locally advanced non metastatic pancreatic cancer
    Mornex, F.
    Chauffert, B.
    Bonnetain, F.
    Triboulet, J.
    Bouche, O.
    Rougier, P.
    Bosset, J.
    Aparicios, T.
    Masskouri, F.
    Bedenne, L.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2007, 69 (03): : S77 - S77
  • [8] Epirubicin (E) in combination with cisplatin (CDDP) and capecitabine (C) versus docetaxel (D) combined with 5-fluorouracil (5-FU) by continuous infusion as front-line therapy in patients with advanced gastric cancer (AGC): Preliminary results of a randomized phase II trial of the Gruppo Oncologico Dell'Italia Meridionale
    Maiello, E.
    De Vita, F.
    Gebbia, V.
    Lorusso, V.
    Cinieri, S.
    Giuliani, F., Sr.
    Orditura, M.
    Fistola, E.
    Filippelli, G.
    Colucci, G., Sr.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
1